ATE271879T1 - Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen - Google Patents

Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen

Info

Publication number
ATE271879T1
ATE271879T1 AT95916293T AT95916293T ATE271879T1 AT E271879 T1 ATE271879 T1 AT E271879T1 AT 95916293 T AT95916293 T AT 95916293T AT 95916293 T AT95916293 T AT 95916293T AT E271879 T1 ATE271879 T1 AT E271879T1
Authority
AT
Austria
Prior art keywords
type
interferons
autoimmune diseases
treating autoimmune
animal
Prior art date
Application number
AT95916293T
Other languages
English (en)
Inventor
Staley Armstrong Brod
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26920717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE271879(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Application granted granted Critical
Publication of ATE271879T1 publication Critical patent/ATE271879T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT95916293T 1994-04-12 1995-04-11 Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen ATE271879T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22663194A 1994-04-12 1994-04-12
US40827195A 1995-03-24 1995-03-24
PCT/US1995/004420 WO1995027502A1 (en) 1994-04-12 1995-04-11 Method of treating auto-immune diseases using type one interferons

Publications (1)

Publication Number Publication Date
ATE271879T1 true ATE271879T1 (de) 2004-08-15

Family

ID=26920717

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95916293T ATE271879T1 (de) 1994-04-12 1995-04-11 Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen

Country Status (13)

Country Link
EP (1) EP0752884B1 (de)
JP (1) JPH09511989A (de)
KR (1) KR100424212B1 (de)
AT (1) ATE271879T1 (de)
AU (1) AU695260B2 (de)
CA (1) CA2187550A1 (de)
DE (1) DE69533311T2 (de)
DK (1) DK0752884T3 (de)
ES (1) ES2224124T3 (de)
IL (1) IL113280A (de)
NZ (1) NZ284276A (de)
SA (1) SA95160081B1 (de)
WO (1) WO1995027502A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US6372206B1 (en) * 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
CA2253971A1 (en) 1996-05-09 1997-11-13 Pharma Pacific Pty.Ltd. Use of high dose interferon by oralmucosal contact to treat viral infections and neoplastic conditions
AUPN976596A0 (en) * 1996-05-09 1996-05-30 Pharma Pacific Pty Ltd Stimulation of host defence mechanisms
SK2942002A3 (en) * 1999-08-27 2002-08-06 Maxygen Aps A conjugate exhibiting interferon beta, a nucleotide sequence, an expressing vector, a host cell containing such a nucleotide sequence, method for the preparation thereof, pharmaceutical composition containing the same and its use
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7431921B2 (en) 1999-08-27 2008-10-07 Maxygen Aps Interferon beta-like molecules
BR0314548A (pt) * 2002-09-27 2005-08-09 Biogen Idec Inc Terapias para polineuropatia de desmielinação inflamatória crÈnica empregando-se interferon-beta
EP1582216A4 (de) 2002-12-26 2010-04-21 Asubio Pharma Co Ltd Heilmittel für pemphigoid
US20210228687A1 (en) * 2018-06-01 2021-07-29 Ilc Therapeutics Ltd Compositions and methods relating to the treatment of diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease

Also Published As

Publication number Publication date
EP0752884B1 (de) 2004-07-28
IL113280A (en) 2004-12-15
JPH09511989A (ja) 1997-12-02
DE69533311D1 (de) 2004-09-02
DE69533311T2 (de) 2005-07-21
AU2283995A (en) 1995-10-30
EP0752884A4 (de) 1999-04-07
ES2224124T3 (es) 2005-03-01
EP0752884A1 (de) 1997-01-15
SA95160081B1 (ar) 2005-09-19
IL113280A0 (en) 1995-07-31
DK0752884T3 (da) 2004-11-22
AU695260B2 (en) 1998-08-13
WO1995027502A1 (en) 1995-10-19
CA2187550A1 (en) 1995-10-19
KR100424212B1 (ko) 2004-07-21
NZ284276A (en) 2000-07-28
KR970702063A (ko) 1997-05-13

Similar Documents

Publication Publication Date Title
ATE338563T1 (de) Verfahren zur behandlung von patienten die unter multipler sklerose leiden mit konsensus- interferon
DK0880350T3 (da) Behandling af dissemineret sklerose
BR9709068A (pt) Processo de tratamento.
ATA162587A (de) Verfahren zur herstellung von neuen benzolderivaten sowie von diese derivate enthaltenden pharmazeutischen zusammensetzungen und verfahren zur verringerung von entzündung bei tieren
DE69033487D1 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
ATE271879T1 (de) Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen
DE69836139D1 (de) Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon
ATE31933T1 (de) Homogenes immuninterferon-fragment.
EP0767666A4 (de) Verfahren und präparate für die prophylaxe und therapie von mit endotoxin verbundenen zuständen
EP0270690A4 (de) Arzneimittel zur behandlung und prophylaxe von leber- und nierenkrankheiten.
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
DE69512760D1 (de) Verwendung von Melatonin zur Behandlung von Patienten die an Drogenabhängigkeit leiden
ATE297722T1 (de) Verwendung von gaba analoga wie gabapentin zur herstellung eines medikaments für die behandlung von entzündungserkrankungen
NO964199L (no) Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller type I interferon
DE69622472D1 (de) Behandlung von Krankheiten durch Induktion von BEF-1 Transkriptionsfaktor
BR9809673A (pt) Derivados de triptolida úteis no tratamento de doenças autoimunes
AT383612B (de) Verfahren zur herstellung eines neuen antigenen proteins des maul- und klauenseuchevirus
DE60015791D1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
EP1150703A4 (de) Chaperonin 10 und beta-interferon therapie für multiple sklerose
ATE222768T1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
ZA952797B (en) Method of treating auto-immune diseases using type one interferons
ATE135912T1 (de) Thienotricyclen zur behandlung von erkrankungen der bronchien
DK0859630T3 (da) Kombination af termozolomid og alfa-IFN til behandling af fremskreden cancer
ATE153859T1 (de) Somatotropin zur erhoehung der reproduktiven leistung in rinder

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0752884

Country of ref document: EP

REN Ceased due to non-payment of the annual fee